Pharma Marketletter

View more issues:

Articles in June, 2004 issue of Pharma Marketletter

• Roche's Xeloda effective as an adjuvant therapy for colon cancer in Phase III trial.
• US FDA raps Abbott over Norvir price claim
• UK govt moves to end OTC ad restrictions
• S Africa High Court reserves judgement on med regs; ruling "by early August".
• Generics slowed rising Rx costs in 2003: PBM.
• US FDA tightens review of outside activities.
• Development of EU OTC market: Liikanen
• Study sees biotech losing ground in May, as US economy stalls, IPO market softens.
• US public opinion of pharma is still on slide.
• Roche's MabThera effective in the treatment of rheumatoid arthritis.
• UPDATE: Two Cipla ARVs off WHO pre-qualification list due to bioequivalence, other problems
• Schering AG reveals restructuring to focus on oncology and gynecology.
• Stock Commentary - New York.
• Cheap-drug policies threaten investment, patient access, BIO speakers warn govts
• Ark's Cerepro raises survival in glioma
• Euro poll: urgent need for clin trial education.
• France's IDM gets bourse listing
• BI's Micardis provides sustained BP control
• Letter from the Editor
  by Lynne Taylor
• Velcade data for MM and NSCLC at ASCO.
• AMA urges registry for all US clinical trials; journal editors mull similar plan
• Take with Care launched in USA to reduce drug errors at home
• Stock Commentary - Europe
• Tokyo pharma stocks - week to June 14.
• Aventis' Taxotere improves survival in men with prostate cancer.
• Choongwae Pharma to launch generic form of Merck & Co's Primaxin.
• Positive data for Maxim's Ceplene
• UK govt's $7.3M for pharmacogenetics.
• GSK clarifies status of paroxetine trial data
• Stock Commentary - Europe
• Novartis' Diovan as effective as Norvasc in hypertensive patients with high CVD risk.
• French generics plan set to hit Rx patents
• Good Ph II results for Novartis' LAF237
• The UK's Strakan to merge with French rival ProSkelia for London-listing.
• Par Pharma buys Kali Labs in $135M deal.
• bioMerieux goes for July listing; major changes and new structure.
• Ph III data for GW's Sativex in MS.
• Solvay awarded $68 million in Barr dispute
• Pancreatic cancer a $1.1 billion US drug market opportunity
• Innovative drugs to drive growth in the oncology market says Natexis Bleichroeder.
• Stada revises forecasts downward
• Teva pays $5M for Active Bio's MS drug.
• Lilly's Gemzar with Taxol improves survival in metastatic breast cancer patients.
• Soy may help reduce risk of developing cancer of the womb.
• Survey reveals challenges facing autoimmune disease research
• News from ASCO; GSK under fire; Editorial
• UK govt study finds "unacceptably high" variation in NICE-backed cancer drug uptake
• Letter from the Editor
  by Barbara Obstoj
• Schering-Plough shares rise on Toyama deal for garenoxacin license.
• Encouraging data for Bayer's BAY 43-9006 in melanoma
• New research shows that self-medication could save EU health care 16.4B euros
• MCO patients cannot sue: US Supreme Court rules
• Is the use of a placebo ethical in cancer trials?
• Tokyo pharma stocks - week to june 14.
• Canada's QLT to buy US firm Atrix Labs in $855 million deal.
• Survey shows deficiencies in arthritis/rheumatism care
• Schering-Plough CEO Hassan discusses pharma industries challenges
• Stock Commentary - New York
• South Africa High Courts suspend medicines regs.
• Sandoz enters generic injectables market with acquisition of Canada's Sabex.
• Hungary: no drug price rises until end-2004.
• US GAO study warns of e-pharmacy risks
• Australian drugmakers rapped over DTC
• Global drug sales up 9% year to April, says IMS.
• Levitra of benefit to diabetic men
• Pfizer's Lipitor trumps in CARDS: halves stroke in type 2 diabetes patients.
• Israel gets closer to self-service OTCs
• Tokyo pharma stocks - week to June 21.
• Onyvax' cancer vaccine shows promise
• Letter from the Editor
• Two Cipla ARVs off WHO pre-qualification list due to bioequivalence, other problems.
• US FDA could award glucosamine and chondroitin health claims by Sept?
• New use in EU for Roche's Herceptin
• Bone health neglected by European women, study shows.
• GSK's Requip significantly improves restless legs syndrome
• Patent expiries and generic competition now facing Japan's drug majors.
• Venture capitalists' pessimism over prospects for Israeli biotechnology.
• New research reveals role of hormones in men